CDV3

Across TCGA pan-cancer cohorts, CDV3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDV3 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDV3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDV3 expression acts as an unfavorable survival marker, although some lineages such as OV and LUAD show a favorable association.

CCRCC, GBM, and OV are the cancer types where CDV3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.545	0.883	<.001	41	view →
GBM	DFS	Median	All	0.265	0.481	.002	19	view →
OV	DFS	Quartile	All	1.000	0.587	.039	8	view →
LUAD	OS	Tertile	All	0.924	0.640	.044	7	view →
PDAC	OS	Quartile	III,IV	0.219	0.538	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDV3–CCRCC (DFS)

Open the CCRCC breakdown →